APIMEDS PHARMACEUTICALS US I

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 03771D102 since 12/18/2024, largest first.

Filer	% of Class	Shares	Form	Filed
Inscobee Inc. 13D/A	34.3%	4,316,618	13D/A	5/7/2026 Event 5/7/2026
Inscobee Inc.	16.7%	2,099,747
Apimeds Inc.	34.3%	4,316,618
Ayrton Capital LLC 13G	10.0%	1,397,021	13G	2/11/2026 Event 12/31/2025
Ayrton Capital LLC	10.0%	1,397,021
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B	10.0%	1,397,021
Waqas Khatri	10.0%	1,397,021

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q2	7	426 k	$384 k	$0
2026 Q1	6	449 k	$803 k	$0
2025 Q4	7	396 k	$649 k	$0
2025 Q3	9	400 k	$712 k	$0
2025 Q2	7	279 k	$490 k	$0